Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 26;13(6):503-520.
doi: 10.4252/wjsc.v13.i6.503.

Immunotherapy in the treatment of lymphoma

Lazar S Popovic  1 , Gorana Matovina-Brko  2 , Maja Popovic  3 , Milica Popovic  4 , Ana Cvetanovic  5 , Ivan Nikolic  3 , Biljana Kukic  3 , Dragana Petrovic  2
Affiliations
Review

Immunotherapy in the treatment of lymphoma

Lazar S Popovic et al. World J Stem Cells. .

Abstract

Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease.

Keywords: Antibodies; Chimeric antigen; Diffuse; Hodgkin disease; Immunoconjugates; Immunotherapy; Large B-cell; Lymphoma; Monoclonal; Receptors.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors have no competing interests to declare.

References

    1. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v116–v125. - PubMed
    1. Hagberg H, Gisselbrecht C CORAL study group. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl 4:iv31–iv32. - PubMed
    1. Philip T, Chauvin F, Bron D, Guglielmi C, Hagenbeek A, Coiffier B, Gisselbrecht C, Kluin Nelemans JC, Somers R, Misset JC. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients) Ann Oncol. 1991;2 Suppl 1:57–64. - PubMed
    1. El Gnaoui T, Dupuis J, Belhadj K, Jais JP, Rahmouni A, Copie-Bergman C, Gaillard I, Diviné M, Tabah-Fisch I, Reyes F, Haioun C. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol. 2007;18:1363–1368. - PubMed
    1. Arcari A, Chiappella A, Spina M, Zanlari L, Bernuzzi P, Valenti V, Tani M, Marasca R, Cabras MG, Zambello R, Santagostino A, Ilariucci F, Carli G, Musto P, Savini P, Marino D, Ghio F, Gentile M, Cox MC, Vallisa D. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study. Leuk Lymphoma. 2016;57:1823–1830. - PubMed